← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,255	-17	-1%	$13.6B
2	2 Charles River Laboratories CRL $14.4B	676	+42	+7%	$14.1B
3	3 CRISPR Therapeutics CRSP $4.86B	483	+13	+3%	$4.1B
4	4 DELISTED CATALENT, INC. CTLT	442	+18	+4%	$10.5B
5	5 Sarepta Therapeutics SRPT $1.78B	415	+19	+5%	$10.8B
6	6 Intellia Therapeutics NTLA $1.6B	285	-8	-3%	$2.51B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	270	+33	+14%	$3.73B
8	8 Vericel Corp VCEL $2.06B	256	+29	+13%	$2.68B
9	9 BridgeBio Pharma BBIO $12.7B	244	-3	-1%	$5.42B
10	10 Krystal Biotech KRYS $9.79B	234	+40	+21%	$4.49B
11	11 Legend Biotech LEGN $3.7B	192	-14	-7%	$4.85B
12	12 Regenxbio RGNX $454M	188	+17	+10%	$897M
13	13 Rocket Pharmaceuticals RCKT $243M	186	-8	-4%	$2.48B
14	14 PTC Therapeutics PTCT $4.98B	184	+11	+6%	$2.48B
15	15 DELISTED Arcellx ACLX	183	+27	+17%	$3.27B
16	16 Fate Therapeutics FATE $232M	167	+8	+5%	$904M
17	17 Allogene Therapeutics ALLO $449M	161	-9	-5%	$586M
18	18 Cabaletta Bio CABA $275M	159	+31	+24%	$871M
19	19 DELISTED bluebird bio BLUE	158	-29	-16%	$134M
20	20 Sana Biotechnology SANA $698M	154	+22	+17%	$1.46B
21	21 Caribou Biosciences CRBU $49.3M	151	+7	+5%	$343M
22	22 DELISTED BioLife Solutions BLFS	149	+9	+6%	$824M
23	23 4D Molecular Therapeutics FDMT $674M	147	+36	+32%	$1.79B
24	24 Voyager Therapeutics VYGR $124M	132	+25	+23%	$331M
25	25 uniQure QURE $1.45B	131	-13	-9%	$172M